+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Hepatocyte-specific contrast media for CT. An experimental investigation

Hepatocyte-specific contrast media for CT. An experimental investigation

Acta Radiologica. Supplementum 411: 1-27

CT is an important technique in liver imaging. To improve the detection of focal liver lesions the use of non-specific, water-soluble contrast media (CM) is mandatory. However, even with use of these CM the sensitivity in tumour detection is low. In the development of liver-specific CM, the majority of the agents have been targeted to the reticuloendothelial system (RES). The clinical use of RES-specific contrast agents has been hampered by frequent adverse reactions, and a new concept whereby the CM is taken up by the hepatocytes has been developed as an alternative. Such a CM is taken up by normal liver parenchyma but not by tumour cells, enhancing the difference between normal and pathological tissue, and therefore improving the diagnostic sensitivity. In the present investigation, FP 736-03 and FP 736-04, two hepatocyte-specific lipid emulsions, have been studied using animal models. In normal liver parenchyma dose-dependent enhancement was found, whereas in tumour tissue of experimental liver metastases and hepatocellular carcinoma, no enhancement was noted. The virtually unchanged attenuation in tumour tissue meant that the liver-to-lesion contrast increased steadily during the observation period. In an attempt to establish the relationship between enhancement and tumour detection, the accumulated doses of FP 736-04 were used. Increasing accuracy in the diagnosis of liver metastases was found up to an enhancement level of 30 HU. A further increase yielded similar detection rates, but a higher proportion of false-positive results. Comparison with iohexol was rendered difficult by the occurrence of image artefacts when this CM was used. However, FP 736-03 proved superior to both native and iohexol-enhanced CT for detection of hepatic metastases. The efficacy of FP 736-04 was also studied in diseased hepatic parenchyma. In cases of fatty liver infiltration, enhancement by FP 736-04 was significantly reduced as compared with normal controls. The degree of enhancement observed in cirrhotic livers did not differ significantly from that in the controls. These preclinical investigations have shown that the hepatocyte-specific lipid emulsions FP 736-03 and FP 736-04 improve the diagnostic accuracy of focal liver lesions as compared to native and water-soluble CM-enhanced CT. FP 736-04 is taken up by diseased liver parenchyma. However, the detection of malignancy in steatotic and cirrhotic livers has not yet been studied with use of this CM.

(PDF emailed within 1 workday: $29.90)

Accession: 046241402

Download citation: RISBibTeXText

PMID: 9164354

Related references

Hepatocyte-specific contrast media: not so simple. Pediatric Radiology 48(9): 1245-1255, 2018

Evaluation of hepatocyte-specific paramagnetic contrast media for MR imaging of hepatitis. Journal of Magnetic Resonance Imaging 3(5): 786-793, 1993

Liver-specific contrast media for magnetic resonance imaging and computed tomography scanning: importance of contrast media for tumor detection in an experimental liver tumor model. Academic Radiology 3 Suppl 2: S420-S422, 1996

Enhancement of liver parenchyma after injection of hepatocyte-specific MRI contrast media: a comparison of gadoxetic acid and gadobenate dimeglumine. Journal of Magnetic Resonance Imaging 31(2): 356-364, 2010

Detecting experimental liver metastases at CT with the hepatocyte-specific contrast medium FP 736-03. Acta Radiologica 39(4): 381-383, 1998

CT with the hepatocyte-specific contrast medium FP 736-04 in an experimental model of liver steatosis. Acta Radiologica 38(3): 405-409, 1997

Magnetic iron oxide for contrast enhanced mr imaging experimental investigation of an organ specific contrast agent. Acta Pharmaceutica Nordica 4(1): 64, 1992

Specific and non-specific contrast media for MRI of tumors. Experimental study of human breast carcinoma. Journal de Radiologie 70(2): 115-121, 1989

CT with different doses of the hepatocyte-specific contrast medium FP 736-03. Evaluation in a nude-rat model of experimental metastases. Acta Radiologica 38(6): 1003-1006, 1997

Efficacy of the hepatocyte-specific contrast medium FP 736-04 for CT in two models of experimental diffuse liver disease. Academic Radiology 5 Suppl 1: S13-5; Discussion S28-30, 1998

Toxicity of bronchographic contrast media: an experimental investigation. Annals of Otology, Rhinology, and Laryngology 69: 1102-1113, 1960

Influence of pre-examination starvation on liver uptake of the hepatocyte-specific contrast medium FP 736-04 at CT. An experimental study in the rat. Acta Radiologica 41(6): 667-670, 2000

Systemic and pulmonary haemodynamic effects of intravenous infusion of non-ionic isoosmolar dimeric contrast media. An investigation in the pig of two ratio 6 contrast media. Acta Radiologica 35(4): 383-390, 1994

Liver-specific contrast media for MRI and CT experimental studies. Acta Radiologica. Supplementum 396: 1-36, 1995

Development and experimental use of receptor-specific MR contrast media. Der Radiologe 36(2): 153-163, 1996